Technical analysis of Supernus Pharmaceuticals, Inc. (SUPN): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention.
Price Performance
| 1 month | -1.77% |
| 3 months | -15.23% |
| Year-to-date | -13.96% |
| 1 year | -11.49% |
| 3 years | +55.83% |
| 5 years | +59.43% |
52-Week Range
| 52-week High | $59.68 |
| 52-week Low | $40.51 |
| Avg Volume (90d) | 791K |
Technical Indicators
| SMA 50 | $44.66 |
| SMA 200 | $48.18 |
| Beta | 0.73 |
| 30-day Volatility (annualised) | 25.8% |
| Price vs SMA 50 | -4.3% |
| Price vs SMA 200 | -11.2% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-11 | $45.59 | |
| 2025-12 | $49.70 | +9.0% |
| 2026-01 | $48.16 | -3.1% |
| 2026-02 | $54.73 | +13.6% |
| 2026-03 | $51.69 | -5.6% |
| 2026-04 | $48.00 | -7.1% |
| 2026-05 | $46.18 | -3.8% |
| 2026-06 | $46.51 | +0.7% |
| 2026-07 | $44.63 | -4.0% |
| 2026-08 | $44.21 | -0.9% |
| 2026-09 | $43.04 | -2.6% |
| 2026-10 | $42.76 | -0.7% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-11-03 | $0.61 | $218M |
| 2026-08-03 | $0.42 | $205M |
| 2026-05-05 | $0.28 | $193M |
| 2026-02-24 | $0.28 | $195M |
| 2025-11-04 | $0.82 | $195M |
| 2025-08-05 | $0.47 | $168M |
| 2025-05-06 | $0.38 | $148M |
Price
| Price | $42.76 |
| Market Cap | $2.5B |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 2.41 |
| EV / EBITDA | -147.59 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.04 |
| Current Ratio | 2.08 |
| Piotroski F-Score | 4 |
| Altman Z-Score | 5.47 |